Elsevier

Clinical Therapeutics

Volume 28, Issue 12, December 2006, Pages 1989-1995
Clinical Therapeutics

The relation between intermittent dosing and adherence: Preliminary insights

https://doi.org/10.1016/j.clinthera.2006.12.011Get rights and content

Abstract

Background:

The past few years have seen a rapid increase in the introduction of drugs with intermittent dosing schedules (ie, dosed less than once daily). Many of these agents were developed on the assumption that less-frequent dosing would be more convenient for patients and thus contribute to improved adherence, with the potential for improvements in the effectiveness of pharmacotherapy and a reduction in the costs of non-adherence. However, the effect on adherence of intermittent dosing regimens has not been studied.

Objective:

This study investigated the evidence to date concerning the effect on adherence of intermittently dosed agents.

Methods:

Articles from peer-reviewed journals were identified through a search of MEDLINE and International Pharmaceutical Abstracts from 2000 to 2005. The search terms included combinations of intermittent dosing, adherence, compliance, dosing schedule, and dosing regimen. The search focused on articles that reported head-to-head comparisons of older agents having more frequent dosing schedules with newer intermittently dosed agents.

Results:

Few head-to-head trials were identified that met the inclusion criteria, as most comparative trials of intermittent and daily agents focused on efficacy rather than adherence. Thus, studies of patient preference for the 2 types of agents were included, as preference may have implications for adherence. Eleven trials met the expanded criteria. Overall, adherence was greater with intermittently dosed agents than with more frequently dosed agents for the same conditions; adherence was 8.8% to 12.0% higher for weekly agents than for agents that were dosed once daily. In the single trial of a once-monthly agent, adherence was similar to that with the daily agent over 1 year (87.4% and 86.6%, respectively). In the studies of patient preference, 61% to 96% of patients preferred the intermittently dosed agent.

Conclusions:

In this preliminary review of the available data, once-weekly dosing was associated with improved patient adherence to therapy compared with once-daily dosing. In the only study of a once-monthly agent, adherence was similar to that with the once-daily agent.

Cited by (67)

  • Asthma Patients Who Stop Asthma Biologics Have a Similar Risk of Asthma Exacerbations as Those Who Continue Asthma Biologics

    2021, Journal of Allergy and Clinical Immunology: In Practice
    Citation Excerpt :

    Unlike ICS/LABA controllers, which must be used every day, most biologics are dosed once or twice a month. Medication possession ratios and treatment persistence have been found to be higher in medications dosed weekly or monthly versus those dosed daily.18-20 Patients who find it difficult to maintain consistent use of a daily controller medication may want to try a less frequently administered controller.

  • Post-use ring weight and residual drug content as potential objective measures of user adherence to a contraceptive progesterone vaginal ring

    2019, Contraception
    Citation Excerpt :

    This assumption is particularly prevalent in the HIV microbicide and multipurpose prevention technology fields, which are heavily focused on new vaginal ring technologies [1–6]. Based on adherence data from other clinical indications [7–9], including hormonal contraception for which depot injections, sub-dermal implants, transdermal patches and vaginal rings are available [10,11], the case for sustained/controlled drug delivery is generally well made and widely accepted. However, a major challenge in vaginal ring product development remains the accurate measurement of adherence in late stage clinical trials [3,12,13], as recently highlighted by the results of the dapivirine ring trials demonstrating increased efficacy in women showing high levels of adherence [14,15].

  • Microbicide vaginal rings: Technological challenges and clinical development

    2016, Advanced Drug Delivery Reviews
    Citation Excerpt :

    It has long been assumed that use of sustained or controlled release delivery systems for vaginal administration of microbicides to prevent infection with HIV will lead to increased microbicide product adherence, acceptability and efficacy compared with more conventional, coitally-dependent, vaginal formulations by simplifying use instructions and requiring less user behavior [15,16,56,215]. Indeed, based on adherence data from other clinical indications [204,216,217], including hormonal contraception for which long-acting depot injections, sub-dermal implants, transdermal patches and VRs are available [218,219], the case for sustained/controlled release of HIV microbicides is generally well made and widely accepted. Previous studies have reported high levels of user adherence to VRs for non-microbicide clinical indications.

  • Once-weekly trelagliptin versus daily alogliptin in Japanese patients with type 2 diabetes: A randomised, double-blind, phase 3, non-inferiority study

    2015, The Lancet Diabetes and Endocrinology
    Citation Excerpt :

    Adherence to treatment for type 2 diabetes is generally better with less frequent dosing.9,11,12,19–21 Patients with chronic illnesses generally prefer intermittent dosing (less than once per day) to once-daily dosing, and a once-weekly oral therapy could improve adherence.8,22 The availability of a once-weekly oral drug for type 2 diabetes might provide an additional treatment option for patients and physicians.

View all citing articles on Scopus
View full text